AXSOME THERAPEUTICS I

Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

03 10 2022 05:30:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

29 9 2022 06:28:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

21 9 2022 06:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

14 9 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

08 9 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

07 9 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 9 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

01 9 2022 06:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

19 8 2022 05:45:03 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

09 8 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

28 7 2022 06:00:02 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

28 6 2022 06:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

22 6 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

06 6 2022 06:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

02 6 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

01 6 2022 06:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

31 5 2022 06:39:37 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

09 5 2022 07:57:19 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience

28 3 2022 05:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum

11 3 2022 06:00:00 提供 Nasdaq GlobeNewswire